Commercial batch production of live H120 avian infectious bronchitis vaccine begins with amplification of a working seed lot in 9- to 11-day-old specific-pathogen-free embryonated chicken eggs under EU GMP Annex 2 biological active substance conditions. Allantoic fluid is harvested 30–36 h post-inoculation, clarified by tangential-flow filtration through 0.45 µm and 0.22 µm polyethersulfone cassettes, and titrated by median embryo infectious dose assay in 9-day-old SPF embryos according to Ph. Eur. 0442. The clarified viral harvest is then diluted into a chilled stabilizer solution containing 4–8% w/v sucrose, 2–4% w/v N-Z-amine type A, and 1–2% w/v hydrolyzed gelatin adjusted to pH 6.8–7.4; the dilution ratio is set between 1:1 and 1:2 harvest-to-stabilizer by volume to target a pre-lyophilization titre of 10⁴·⁵–10⁵·⁵ EID₅₀ per chick dose. The stabilised liquid is filled into siliconized type I borosilicate glass vials of 2 mL, 5 mL, or 10 mL nominal capacity and loaded into a shelf lyophilizer equipped with a controllable shelf temperature from -55 °C to +30 °C and a chamber vacuum of 50–200 µbar. The lyophilization cycle holds the product at -45 °C for 4–6 h, ramps primary drying from -35 °C to -10 °C over 20–24 h at 60–100 µbar, and completes secondary drying at +20 °C for 6–12 h to reach a residual moisture content of 1.0–2.0% w/w. Post-lyophilization titre loss is typically 0.2–0.5 log₁₀ EID₅₀ under these parameters; excursions above 2.5% w/w residual moisture or collapsed cake morphology are typical batch failure signals observed on commercial lines. The terminal finished product is a lyophilized plug for reconstitution in drinking water, delivering a monovalent live infectious bronchitis virus vaccine with a minimum release titre of 10³·⁰ EID₅₀ per chick dose. This manufacturing route is the primary downstream application of the H120 active antigen for broiler producers and vaccine license holders in the European, Latin American, and Southeast Asian markets.

Why does drinking-water matrix pH and chlorine residual depress viable H120 titre before first sip?

The drinking-water route remains the dominant field administration method for H120 lyophilized powder because it allows simultaneous exposure of large broiler populations without individual bird handling, but it is also the route where microbial viability is most sensitive to water matrix parameters. The reconstituted vaccine is injected into the drinking line via a proportioner set to deliver 10–20 L of final medicated water per 1,000 doses, corresponding to a typical one-dose volume of 10–20 mL per bird for broilers aged 7–14 days; actual volume is adjusted to the water consumption rate over 1–2 h after water withdrawal. Before reconstitution, free chlorine must be neutralized below 0.1 mg/L because chlorine residuals are virucidal to live H120; the exact inactivation rate depends on organic load, water temperature, and contact time, and published data for specific field matrices is limited. Skim milk powder at 2.5 g/L of drinking water or sodium thiosulfate at 0.05% w/v is commonly used as a chlorine-neutralizing agent; the water pH is maintained between 6.5 and 7.5 because alkaline conditions above pH 8.0 accelerate capsid destabilization. The lyophilized H120 plug is first reconstituted in a clean plastic or stainless steel mixing vessel with 1–2 L of cooled, chlorine-free water at 8–20 °C, then diluted through the dosing pump into the main line. The final medicated water is consumed within 2 h; any residual volume after 2 h is discarded due to expected titre loss under field conditions. Compliance for the finished product remains governed by Ph. Eur. 0442 and 9 CFR 113.327 at batch release, while field application follows the manufacturer’s validated water-administration instructions submitted to the competent veterinary regulatory authority. Terminal finished product types for this route are lyophilized powder for oral suspension and the corresponding water-soluble powder presentation; the vaccine is never supplied as an injectable for drinking-water use.

Through co-formulation of H120 live infectious bronchitis virus with lentogenic Newcastle disease virus, vaccine manufacturers produce bivalent lyophilized vaccines that reduce hatchery labour and simplify vaccination calendars on multi-age farms. In this production route, each monovalent allantoic fluid harvest is separately clarified, stabilised, and titrated before blending. The H120 component is typically added as 25–50% v/v of the final virus blend, with the exact ratio determined by the individual harvest titre and the target fill titre, which is generally 10³·⁵–10⁴·⁰ EID₅₀ per dose for H120 and 10⁶·⁰ EID₅₀ per dose for Newcastle disease virus in the same finished plug. The combined liquid is mixed at 4–8 °C for 30–60 min under continuous low-shear agitation to avoid mechanical damage to the enveloped Newcastle disease virus component, then filled into vials and lyophilized under the same pH and residual moisture constraints described for monovalent H120; because the two viruses differ in thermosensitivity, the formulation uses a two-stage stabilizer addition step with sucrose and hydrolyzed gelatin providing the primary cryoprotectant matrix for both viruses. Production-scale failures in this combined route are most commonly linked to lot-to-lot variation in allantoic fluid titre and to pH drift during blending, which affects the more fragile H120 component before freezing begins. The terminal finished product is a bivalent freeze-dried vaccine plug for drinking-water or coarse-spray administration, legally classified as a live avian infectious bronchitis and Newcastle disease vaccine and tested against both Ph. Eur. 0442 and the corresponding Newcastle disease vaccine monograph with batch release confirmed by EID₅₀ titration in SPF embryonated eggs.

When coarse-spray administration in hatchery cabinets dictates a narrower reconstitution volume than drinking-water use

Hatchery coarse-spray vaccination uses the same lyophilized H120 plug but imposes tighter constraints on reconstituted water volume, droplet spectrum, and post-spray chick drying because the vaccine must deposit infectious virus onto the conjunctival and upper respiratory mucosa within seconds rather than after sustained drinking-water ingestion. The standard reconstitution ratio is 1,000 doses in 200–400 mL of cool distilled or deionized water, producing a final suspension that is sprayed onto day-old chicks inside a ventilated cabinet with a droplet size distribution of 100–250 µm volume median diameter; droplet sizes above 300 µm cause rapid fallout and reduce dose uniformity, while particles below 50 µm penetrate too deeply and may trigger respiratory reactions. Cabinet air temperature is maintained at 20–25 °C with relative humidity 55–70%, and exhaust air flow is calibrated to avoid recirculation of aerosol into the operator zone. The production process from the B2B buyer’s perspective is not merely reconstitution: the vaccine must be formulated with a surfactant-free stabilizer that does not foam during pressure-pot sprayer operation, because foam alters nozzle flow and reduces the recoverable titre in the collected spray. The terminal finished product type is a lyophilized plug for suspension for spraying, sometimes presented as a wider-neck vial to allow rapid reconstitution under hatchery time pressure. Compliance at batch release remains Ph. Eur. 0442 and 9 CFR 113.327, while the spray equipment itself is validated under the vaccine marketing authorisation holder’s instructions; published data for specific nozzle brands and cabinet designs are limited, requiring site-specific uniformity trials before registration in most jurisdictions.

Individual bird oculonasal delivery is used principally in layer and breeder rearing programs where documentation of individual vaccination and reduction of bird-to-bird contact transmission are more important than labour efficiency. The lyophilized H120 plug is reconstituted in sterile phosphate-buffered saline or manufacturer-supplied diluent at 1,000 doses per 30–35 mL, yielding a one-dose volume of 0.03 mL for each drop; the pH of the diluent is held at 6.8–7.4 and the temperature at 15–25 °C during the vaccination session. The downstream production step for this presentation is not a new formulation but a filling-line adaptation: vaccine manufacturers package the lyophilized plug with a separate diluent bottle, and the dropper tip or pre-mounted cannula is selected to deliver 0.03 mL with a tolerance of ±10%. Terminal finished product types include lyophilized powder and solution for oculonasal use; the solution is reconstituted immediately before use and cannot be stored beyond 2 h at field temperature. The compliance framework is governed by Ph. Eur. 0442 for the virus titre and by VICH GL44 for target animal safety in the route-specific registration file; batch release testing includes visual inspection of the lyophilized cake, residual moisture 1.0–2.0% w/w, and sterility of the diluent. Parenteral injection is not an approved route for live H120, and any request for an injectable presentation would require a different inactivated antigen platform, which lies outside this API’s licensed application scope.

Low-dust granulated powder for automated drinking-line dosing and the exclusion of tablet, capsule, and injectable routes

Unlike synthetic chemical APIs, live H120 antigen cannot be freely transferred into conventional solid oral dosage forms because the residual moisture and shear forces associated with tableting and capsule filling are not compatible with the viral titre stability required by Ph. Eur. 0442. Tablet compression on a rotary tablet press with compression force above 5 kN per tablet is considered high risk for live viral infectivity; however, published data for this specific configuration is limited, and no H120 live vaccine tablet has been recognized in major pharmacopoeial compendia. Capsule filling of lyophilized powder into hard gelatin capsules is similarly constrained by moisture uptake above 1.0% w/w unless handled under relative humidity below 20% and sealed with desiccant; this has not replaced the standard vial presentation. Granular premixes or feed-grade premix intermediates for the H120 live antigen are not validated because dry heat and pellet milling temperatures above 40 °C are incompatible with the thermolability of the live virus. Where a low-dust granulated water-soluble presentation is requested for automatic dosing systems, the safer approach is to blend the lyophilized H120 powder into a water-soluble carrier powder using gentle tumble blending at 4–8 °C and RH <30%, with an addition ratio of 10–20% w/w H120 powder to carrier, and to package the blend in aluminium-foil sachets with desiccant. The terminal finished product types that can be supported are limited to lyophilized powder for reconstitution and water-soluble powder or granule for oral suspension, whereas tablet, capsule, injection, and feed-grade premix presentations should be excluded from downstream development decisions without a dedicated stability and potency validation package. This section is deliberately restrictive because the central B2B decision for buyers is not the addition ratio itself but the route-dependent viability boundary of a live viral antigen.